Moberg Pharma
Moberg Pharma AB is a Swedish pharmaceutical company focused on the development and commercialization of medical products, particularly in the area of dermatology. The company is known for its innovative treatments for nail fungus, with its flagship product MOB-015 receiving approval in multiple European countries. Moberg Pharma operates primarily through strategic partnerships, allowing it to leverage local expertise for marketing and distribution while focusing its resources on research and development. The company aims to expand its market presence in Europe and eventually enter the U.S. market pending further clinical studies and FDA approval.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueIncludes MOB-015 and related products for nail fungus treatment
Revenue from partnerships for product distribution
R&D services for pharmaceutical development
Customers
Moberg Pharma primarily serves pharmaceutical companies and healthcare providers through its strategic partnerships. These partners are responsible for marketing and selling Moberg's products in their respective regions, such as Europe, Canada, and Israel. The company's products are targeted at adults suffering from mild to moderate fungal infections, with a focus on providing effective and convenient treatment options. Moberg Pharma's business model allows it to maintain a lean operational structure while leveraging the marketing and distribution capabilities of its partners.
Partners who market and distribute MOB-015 in specific regions
Providers offering MOB-015 to patients with nail fungus
Adults using MOB-015 for nail fungus treatment
Strategy
Moberg Pharma's strategic priorities include expanding its market presence in Europe and preparing for a future U.S. launch. The company leverages strategic partnerships to distribute its products, allowing it to focus on R&D and product development. Moberg Pharma aims to enhance its product portfolio through acquisitions and partnerships, positioning Terclara as a premium brand. The company is also focused on generating additional clinical data to support FDA approval for its products in the U.S.
To establish a strong market presence and drive revenue growth
To access the largest market for onychomycosis treatments
Geography
Moberg Pharma is headquartered in Sweden and has a significant presence in Europe through its partnerships. The company has secured national approvals for its products in 13 European countries and is actively expanding its market presence. In addition to Europe, Moberg Pharma has partnerships in Canada and Israel, enabling a broader geographic reach. The company's long-term strategy includes entering the U.S. market, which is the largest market for onychomycosis treatments globally.
Risks
Moberg Pharma faces several risks typical of the pharmaceutical industry, including regulatory challenges, market risks, and the need for continuous innovation. The company's success depends on the outcomes of clinical trials and obtaining necessary regulatory approvals. Financial risks include the need for substantial capital investment and sensitivity to economic fluctuations. Additionally, the company relies on key partnerships for distribution, which poses a risk if these partnerships are disrupted.
- Clinical Trial OutcomesImpact: CriticalLikelihood: Medium
Negative results could impact product development
- Regulatory Approval DelaysImpact: HighLikelihood: Medium
Could delay market entry and revenue generation
- Partnership DisruptionsImpact: HighLikelihood: Low
Could affect distribution and sales
Accounting
Judgemental itemsImpacts future financial results as amortization begins
Impact: high
Based on milestone payments leading to revenue fluctuations
Impact: medium
Similar listed companies
Publicly listed companies with a comparable business focus.
Vimian Group
VIMIAN · Health Care
Vimian Group is a company focused on the animal health sector, providing a range of products and services across four segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics.
Xbrane Biopharma
XBRANE · Health Care
Xbrane Biopharma AB is a biotechnology company specializing in the development of biosimilars, which are follow-up drugs introduced at a lower price after the original drug's patent expires.
Ascelia Pharma
ACE · Health Care
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey.
MediciNova, Inc
MNOV · Pharmaceutical Preparations
MedicNova Inc.
IRLAB Therapeutics
IRLAB-A · Health Care
IRLAB Therapeutics is a Swedish biopharmaceutical company focused on discovering and developing novel treatments for Parkinson's disease and other central nervous system (CNS) disorders.
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Last updated: 24/09/2026